Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer
Clinical trial NCT07670273 · RECRUITING
Trial details
- NCT number
- NCT07670273
- Sponsor
- Peking Union Medical College Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-29
- Primary completion
- 2027-04-29
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.